Acute kidney injury: cell cycle arrest biomarkers win race for AKI diagnosis

Nat Rev Nephrol. 2014 Dec;10(12):683-5. doi: 10.1038/nrneph.2014.198. Epub 2014 Oct 28.

Abstract

FDA approval of the first device to use novel biomarkers of kidney damage to assess risk of acute kidney injury (AKI) potentially brings forward diagnosis of moderate-to-severe AKI to a time frame that could enable early intervention. Although the device awaits greater scrutiny, its approval marks the beginning of a new era.

MeSH terms

  • Acute Kidney Injury / diagnosis*
  • Acute Kidney Injury / pathology
  • Acute Kidney Injury / prevention & control
  • Acute Kidney Injury / urine*
  • Biomarkers / urine
  • Cell Cycle Checkpoints*
  • Early Diagnosis*
  • Female
  • Fluoroimmunoassay / methods
  • Humans
  • Insulin-Like Growth Factor Binding Proteins / urine*
  • Male
  • Matrix Metalloproteinase 2 / urine*
  • Point-of-Care Systems
  • Sensitivity and Specificity
  • United States
  • United States Food and Drug Administration

Substances

  • Biomarkers
  • Insulin-Like Growth Factor Binding Proteins
  • Matrix Metalloproteinase 2